ESG reporting center
Organon regularly reports on our performance on ESG and sustainability-related topics through our annual ESG Report and other publications.
About this report
ESG reporting disclaimer
The information contained on this webpage and in our ESG reports (collectively ESG Report) is intended to comply with the general principles, laws, rules and regulations related to environmental, social and governance (ESG), sustainability or corporate responsibility.
However, please be aware that ESG standards and regulatory requirements may vary significantly across different jurisdictions. As such, depending on your country of residence or incorporation, there may be specific local requirements or standards that the ESG Report does not fully address. We encourage you to consider your local requirements and your own ESG criteria and objectives when selecting our products and services.
It should be noted that no universally accepted global framework (legal, regulatory or otherwise) currently exists, nor is there a market consensus in terms of what constitutes a “green,” “sustainable,” “responsible,” “traditional” or equivalent “ESG” investment, communication, product or offering. However, as regulatory expectations are emerging, Organon is assessing the alignment of its sustainability reporting, including with the European Union’s Corporate Sustainability Reporting Directive (CSRD), the European Sustainability Reporting Standards (ESRS) and other evolving frameworks in the jurisdictions where we operate.
Additionally, the lack of common or harmonized definitions and labels currently regarding what is considered “green,” “ESG,” “sustainable,” “responsible” and other similar criteria or clear guidelines on what these terms mean may result in different approaches being taken by different institutions.
Accordingly, given that this ESG Report is voluntary and is not intended to satisfy any particular legal, regulatory, accounting, investment or disclosure framework except as specifically identified herein, no assurance, warranty or representation can be given by Organon & Co., Inc., or any of its subsidiaries or affiliated companies, that it will meet any or all expectations regarding “green,” “ESG,” “sustainable,” “responsible” or other equivalently labeled objectives.
In addition, the providers of any opinions, certifications, reviews and validations in connection with Organon programs and/or frameworks are not currently subject to any specific regulatory or other regime or oversight. Any such opinion, certification, review and validation issued in connection with Organon programs and/or frameworks is not, nor should it be deemed to be, a recommendation by us or any opinion or certification provider, external verifier or any other person. All of this information involves a variety of assumptions, limitations and methodologies, and is inherently subject to uncertainties; therefore, you are cautioned not to give undue weight to them. Prospective consumers of the ESG Report must determine for themselves the relevance of any such opinion, certification, review or validation and/or the information contained therein and/or the provider of such opinion, certification, review or validation.
On April 26, 2026, Organon entered into a definitive agreement with Sun Pharmaceutical Industries Limited (“Sun Pharma”) under which Sun Pharma will acquire all of Organon’s outstanding shares of common stock. The transaction is expected to close in early 2027, subject to customary closing conditions, including receipt of required regulatory approvals. The achievement, timing and implementation of the ESG goals, priorities and initiatives described in this report may be affected by the completion of the transaction and future decisions of the combined organization.
Cautionary note regarding forward-looking statements
Some statements and disclosures on or available through this webpage are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “aims,” “targets,” “goals,” “will” or words of similar meaning. Forward-looking statements include, without limitation, statements regarding our ESG strategy, priorities, objectives, targets, ambitions, commitments and goals, including our 2030 ESG goals, any anticipated environmental, social, governance, operational, business or other benefits associated therewith, and statements regarding our proposed merger with Sun Pharmaceutical Industries Limited. These forward-looking statements are based on our current plans, expectations, assumptions and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, among others, changes in business, market, economic, regulatory or political conditions; evolving stakeholder expectations; the availability, quality and assumptions underlying the data used in preparing ESG-related metrics and disclosures; our ability to implement ESG-related initiatives; changes in our business strategy, capital allocation priorities or organizational structure; supplier, partner and third-party participation; and the risks and uncertainties described in our filings with the Securities and Exchange Commission (“SEC”), including those relating to the pending acquisition of the Company by Sun Pharmaceutical Industries Ltd. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the SEC, including Organon’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent SEC filings, available at the SEC’s website.
ESG disclosures
Our disclosures are informed by the International Financial Reporting Standards (IFRS) Foundation’s Sustainability Accounting Standards Board (SASB) and the Global Reporting Initiative (GRI) standards for our industry, as well as the Task Force on Climate-Related Financial Disclosures (TCFD) framework, the Greenhouse Gas Protocol (GHG Protocol) and feedback from stakeholders, including employees, investors and ESG ratings agencies. We also support and align our reporting to the United Nations Sustainable Development Goals (U.N. SDGs). This priority-based approach to ESG reporting helps ensure that we can continue to build a meaningful ESG strategy that responds to external events, evolving business priorities, stakeholder expectations and our own performance results.
Additionally, we publicly share our relevant policy documents that provide a detailed map for how we can deliver on our mission.
Our approach to ESG and stakeholder engagement
We believe that by advancing the complete health of women, we advance the health of society. And our ESG strategy helps ensure we deliver on our corporate vision: a better and healthier every day for every woman.
In 2025, we refreshed our ESG strategy to reflect evolving regulatory requirements, changes in the external operating environment and shifting stakeholder expectations. As part of this process, we reviewed our ESG priority topics to ensure continued alignment with our strategy, business priorities and stakeholder interests. This topic prioritization exercise informed the areas we chose to emphasize within our refreshed strategy and helped shape our new 2030 goals across Her equity, Her planet and Her trust. While our ESG topics remain grounded in the issues most relevant to our business, our refreshed strategy places particular emphasis on three priority areas where we believe we can make the greatest impact: access to medicines and healthcare, innovation for women’s health and education. Education was elevated as a strategic priority because it serves as a critical enabler across our ESG efforts, helping to build awareness, strengthen understanding and support informed decision-making among key stakeholders, including policymakers, healthcare providers, patients and the communities we serve. By advancing education alongside access and innovation, we aim to help improve health outcomes worldwide.
Alignment with the U.N. Sustainable Development Goals
Organon supports the U.N. SDGs. Specifically, our purpose as a company aligns with gender equality and good health and well-being, as well as other goals.
We work to advance the U.N. SDGs inside and outside our company. We are a participant in the U.N. Global Compact and adhere to its principles-based approach to responsible business. Organon is also a signatory to the U.N. Global Compact’s Women’s Empowerment Principles and CEO Water Mandate.
Report downloads
Performance data tables
Throughout the year, we used a data-driven and dynamic qualitative and quantitative process for ESG risk identification and monitoring. The performance data tables below cover the full enterprise of Organon and all our legal entities for the 2025 calendar year (January 1, 2025, through December 31, 2025) unless otherwise stated. All dollar amounts are listed in U.S. dollars.
GRI Index
The GRI standards represent global best practices for reporting publicly on a range of economic, environmental and social impacts. The tables in this document summarize where responses to the GRI disclosures can be found throughout our website.
SASB Index
SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors. The tables in this document summarize how our existing reporting aligns with the recommended metrics for the Biotechnology & Pharmaceuticals Standard within the Healthcare sector and where this information can be found throughout our website.
TCFD Index
We believe that an effective response to climate change is a key element of our commitment to women’s health and our vision of creating a better, healthier every day for every woman. The document below summarizes how our reporting aligns with the recommended disclosures found within the TCFD framework.
Learn more about our policies and positions.